Reference
Choi H, et al. Acquired TPM3-NTRK1 fusion resistant to larotrectinib in a non-small cell lung cancer with EML4-ALK fusion progressed on lorlatinib. Cancer Research 82 (Suppl.): abstr. 4120, No. 12, Jun 2022. Available from: URL: https://aacrjournals.org/cancerres/article/82/12_Supplement/4120/704317/Abstract-4120-Acquired-TPM3-NTRK1-fusion-resistant
Rights and permissions
About this article
Cite this article
Antineoplastics. Reactions Weekly 1921, 36 (2022). https://doi.org/10.1007/s40278-022-22030-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-22030-0